Korea Toujeo OK Sets Stage for Tresiba Clash
This article was originally published in PharmAsia News
Executive Summary
Sanofi's next-generation basal insulin Toujeo has been approved in South Korean and looks set to compete with Novo Nordisk's Tresiba, which is also expected to be launched there soon.